These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25465967)

  • 21. The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer.
    Shiota M; Yokomizo A; Adachi T; Koga H; Yamaguchi A; Imada K; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
    Jpn J Clin Oncol; 2014 Sep; 44(9):860-7. PubMed ID: 24951829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leading causes of castration-resistant prostate cancer.
    Lu M; Lu H; Kong Q
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of advanced prostate cancer.
    von Eyben F; Kiljunen T; Kangasmaki A; Kairemo K; von Eyben R; Joensuu T
    Ann Oncol; 2015 Nov; 26(11):2354. PubMed ID: 26216387
    [No Abstract]   [Full Text] [Related]  

  • 24. Understanding heterogeneity of treatment effect in prostate cancer.
    Aly A; Mullins CD; Hussain A
    Curr Opin Oncol; 2015 May; 27(3):209-16. PubMed ID: 25689354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
    Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
    Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Castration-resistant prostate cancer: adaptive responses in the androgen axis.
    Egan A; Dong Y; Zhang H; Qi Y; Balk SP; Sartor O
    Cancer Treat Rev; 2014 Apr; 40(3):426-33. PubMed ID: 24139549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
    Crona DJ; Milowsky MI; Whang YE
    Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
    Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
    Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
    Bastos DA; Dzik C; Rathkopf D; Scher HI
    Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucocorticoids and prostate cancer treatment: friend or foe?
    Montgomery B; Cheng HH; Drechsler J; Mostaghel EA
    Asian J Androl; 2014; 16(3):354-8. PubMed ID: 24625881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.
    Giacinti S; Carlini P; Roberto M; Bassanelli M; Strigari L; Pavese F; Aschelter AM; Felici A; Valeriani M; Cognetti F; Marchetti P
    Anticancer Drugs; 2017 Jan; 28(1):110-115. PubMed ID: 27763885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phytoestrogens selective for the estrogen receptor beta exert anti-androgenic effects in castration resistant prostate cancer.
    Thelen P; Wuttke W; Seidlová-Wuttke D
    J Steroid Biochem Mol Biol; 2014 Jan; 139():290-3. PubMed ID: 23872207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy and problems of new hormonal agents for the treatment of castration resistant prostate cancer].
    Hakariya T; Sakai H
    Nihon Rinsho; 2016 Jan; 74(1):137-42. PubMed ID: 26793894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GPX2 overexpression is involved in cell proliferation and prognosis of castration-resistant prostate cancer.
    Naiki T; Naiki-Ito A; Asamoto M; Kawai N; Tozawa K; Etani T; Sato S; Suzuki S; Shirai T; Kohri K; Takahashi S
    Carcinogenesis; 2014 Sep; 35(9):1962-7. PubMed ID: 24562575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Castration resistant prostate cancer 2011].
    Miller K
    Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Galeterone activity in castration-resistant prostate cancer.
    Yaqub F
    Lancet Oncol; 2015 Jan; 16(1):e10. PubMed ID: 25638544
    [No Abstract]   [Full Text] [Related]  

  • 37. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.
    Anantharaman A; Small EJ
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):625-633. PubMed ID: 28532278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Castration-naive metastatic prostate cancer: reshaping old paradigms.
    Ratta R; Grassi P; Fucà G; Verzoni E; Procopio G
    Expert Rev Anticancer Ther; 2017 Oct; 17(10):879-881. PubMed ID: 28854837
    [No Abstract]   [Full Text] [Related]  

  • 39. Agents that target androgen synthesis in castration-resistant prostate cancer.
    Ferraldeschi R; de Bono J
    Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reply to the letter to the editor 'management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015' by Gillessen et al.
    Gillessen S; Fanti S; Omlin A;
    Ann Oncol; 2015 Nov; 26(11):2354-5. PubMed ID: 26347101
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.